Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Vancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality

Authors Alshehri N, Ahmed AE, Yenugadhati N, Javad S, Al Sulaiman K, Al-Dorzi HM, Aljerasiy M, Badri M

Received 18 June 2020

Accepted for publication 6 September 2020

Published 14 October 2020 Volume 2020:16 Pages 979—987

DOI https://doi.org/10.2147/TCRM.S266295

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Nadiyah Alshehri,1,2 Anwar E Ahmed,3 Nagarajkumar Yenugadhati,2,4 Sundas Javad,2,4 Khalid Al Sulaiman,1 Hasan M Al-Dorzi,5 Majed Aljerasiy,4 Motasim Badri2,4

1Pharmaceutical Care Department, Ministry of National Guard- Health Affairs, Riyadh, Saudi Arabia; 2Department of Epidemiology & Biostatistics, College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 3Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; 4King Abdullah International Medical Research Center, King Saud Bin-Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 5Intensive Care Department, College of Medicine King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

Correspondence: Nadiyah Alshehri
Department of Epidemiology & Biostatistics, College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, P.O. Box: 47323, Riyadh 11552, Saudi Arabia
Email alshehrina2@ngha.med.sa

Background: Vancomycin is one of the most common therapeutic agents for treating gram-positive infections, particularly in critically ill patients. The aim of this study was to identify factors associated with initial therapeutic vancomycin trough levels and mortality in a tertiary-care intensive care unit (ICU).
Methods: This retrospective study evaluated 301 adult ICU patients admitted to King Abdulaziz Medical City in Riyadh between October 1, 2017 and December 31, 2018 with confirmed gram-positive infections and received intravenous vancomycin. Vancomycin trough levels of 15– 20 mg/L for severe infections and 10– 15 mg/L for less severe infections were considered therapeutic.
Results: The patients were relatively older with a mean age of 60 (SD ± 20) years. Initial vancomycin trough levels were therapeutic in 168 (55.8%). Factors associated with initial therapeutic vancomycin trough levels were female gender (adjusted odds ratio [aOR]=2.575), older age (aOR=1.024), receiving a loading dose (aOR=2.445), having bacteremia (aOR=2.061), and high platelet count (aOR=1.003). On the other hand, the increase of estimated glomerular filtration rate (eGFR) (aOR=0.993) and albumin levels (aOR=0.944) were associated with lower odds of initial therapeutic vancomycin trough levels. Factors associated with higher mortality were female gender (adjusted hazard ratio [aHR]=2.630), increased body weight (aHR=1.021), cancer (aHR=3.451), and high APACHE II score (aHR=1.068).
Conclusion: The study identified several factors associated with achieving initial therapeutic vancomycin trough levels (i.e. older age, female gender, receiving a loading dose, bacteremia, high platelets count, low eGFR and albumin level). These factors should be considered in the dosing of vancomycin in critically ill patients with gram-positive infections.

Keywords: vancomycin dosage, pharmacokinetics, renal function, serum trough levels, mortality

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]